Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 01 12; 393(10167):156-167.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Cetuximab
Disease Progression
Drug Administration Schedule
Female
Head and Neck Neoplasms
Humans
Kaplan-Meier Estimate
Male
Methotrexate
Middle Aged
Neoplasm Recurrence, Local

authors with profiles

Ezra Cohen